Phase 2 N=55 Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma
Esophageal Cancer
Primary: Number of Participants With Overall Response Rate (RR) — 44 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=28 Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)
Esophageal Squamous Cell Carcinoma
Primary: Complete Pathologic Response Rate — 6 Participants
Phase 2 N=25 Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
Esophageal Squamous Cell Carcinoma
Primary: 1-year Relapse-free Survival Rate — 14.3 months
N/A N=96 Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia
ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Primary: Complete Response — 81 Participants
Phase 1 N=20 Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus
Esophageal Squamous Cell Carcinoma
Primary: Safety (Number of Participants With Grade 3 and Higher-grade Treatment-related Adverse Events) — 13 Participants
Phase 2 N=60 Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
Phase 2 N=125 Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
Primary: Objective Response Rate (ORR) Assessed by the Investigator — 30.6; 20.6 percentage of participants — p=0.2114
Phase 2 N=15 A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
Cancer
Primary: Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments. — 15; 14; 12; 13 number of adverse events
Phase 3 N=749 First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)
Esophageal Neoplasms
Primary: Overall Survival (OS) in Participants With Esophageal Squamous Cell Carcinoma (ESCC) Whose Tumors Are Programmed Cell Death-Ligand 1 (PD-L1) Biomarker-Positive (Combined…
Phase 2 N=190 A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Primary: Overall Survival (OS) — 8.08; 4.76; 6.67 months — p=0.7689
Phase 3 N=370 A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
Primary: Progression-free Survival (PFS) — 29.0; 28.9 months — p=0.3016
Phase 2 N=74 Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer
Esophageal Cancer
Primary: Rate of Participants Who Were Alive at 2 Years — 71; 53 percentage of participants
Phase 2 N=62 Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
Esophageal Cancer
Primary: Pathologic Complete Response (pCR) Rate — 18 Participants
Phase 2 N=190 Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment
Esophageal Squamous Cell Carcinoma
Primary: Overall Survival — 7.23; 6.21 month — p=0.032
Phase 3 N=514 Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma
Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy
Primary: PFS((Progression-Free Surviv) — 5.7; 5.5 months
Phase 3 N=512 A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
Primary: Overall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set — 8.6; 6.3 Months — p=0.0001
Phase 2 N=22 Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer
Esophageal Cancer
Primary: Overall Survival — 7.3 months
Phase 2 N=98 S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction
Esophageal Cancer
Primary: Pathological Complete Response — 26 participants
Phase 2 N=70 Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
Resectable Esophageal Squamous Cell Carcinoma
Primary: Pathological Complete Response (pCR) Rate — 30.0; 34.4 percentage of participants
Phase 2 N=73 Endoscopic Therapy of Early Cancer in Barretts Esophagus
Early Stage Esophageal Adenocarcinoma · Barrett Esophagus
Primary: Level of Dysplasia on Histology at 12 Months — 10; 11; 15; 2 paricipants — p=0.0098
Phase 3 N=649 A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
Primary: Overall Survival (OS) — 17.2; 10.6 months — p=<0.0001
Phase 2 N=35 Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
Esophageal Cancer · Gastroesophageal Junction Cancer
Primary: 2-month Progression-free Survival (PFS) of Sorafenib in Patients With Metastatic or Recurrent Esophageal and Gastroesophageal (GE) Junction Cancer. — 20; 14; 1…
Phase 2 N=121 Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)
Esophageal Carcinoma · Esophagogastric Junction Carcinoma
Primary: Objective Response Rate (ORR) According to Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR)…
Phase 2 N=4 Trimodality Management of T1b Esophageal Cancers
Esophageal Cancer
Primary: Pathologic Complete Response (PCR) Rate
Phase 2 N=14 Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Median Overall Survival — 231 Days
N/A N=50 Esophageal Cytology With FISH in Detecting Esophageal Cancer
Dysphagia · Dysplasia · Esophageal Adenocarcinoma
Primary: Sensitivity of Sponge Cytology Using FISH — 13.3 percentage of cases among positive tests
Phase 2 N=41 Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas
Esophageal Cancer
Primary: Complete Pathologic Response (pCR) — 36.6 percentage of participants
Phase 3 N=448 Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
Esophageal Carcinoma
Primary: Overall Survival (OS) — 8.28; 6.24 months
Phase 2 N=43 Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Esophageal Cancer
Primary: Overall Survival (1-year Rate Reported) — 71 percentage of participants
Phase 2 N=63 S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Esophageal Cancer
Primary: Overall Survival at 6 Months — 36 percentage of participants